Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. - 11:00 a.m. ET in New York, NY. The event will be hosted by members of the Adamas executive management team and will feature presentations...
Sep 13, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees stock options to purchase an aggregate of 15,450 shares of the company's common stock, at a per share exercise price of $20.77, the closing...
Sep 11, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive topline data from the Phase 1b clinical trial of ADS-4101 (lacosamide) modified-release capsules. The study demonstrated that a 600 mg dose of ADS-4101, taken once-nightly, provided a 1.7-fold increase in average lacosamide c...
Sep 7, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with ...
Aug 24, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. "This is a very exciting time for Adamas, as we are potentially at the cusp of transitioning from a company focused on product development to a c...
Aug 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the fi...
Aug 1, 2017 General Releases HTML PDF
EMERYVILLE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G. Merriweather. The compensation committee of the company's board of directors granted Mr. Merriweather a stock option to purchase 112,500 shares of the company'...
Jul 10, 2017 General Releases HTML PDF
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive Officer, and the retirement of William J. Dawson, its former Chief Financial Officer. Mr. Merriweath...
Jun 28, 2017 General Releases HTML PDF
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia -- -- New Drug Application for ADS-5102 Currently Under FDA Review with August 24, 2017 PDUFA Date-- EMERYVILLE, Calif., June 12, 2017 (GLOBE NEWSWIRE...
Jun 12, 2017 General Releases HTML PDF
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia currently under FDA review with August 24, 2017, PDUFA date -- EMERYVILLE, C...
Jun 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company's Chairman and Chief Executive Officer, is scheduled to present at two upcoming investor conferences: Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 9:30 a.m. ET J...
Jun 1, 2017 General Releases HTML PDF
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study ongoing, with topline data expected in the third quarter 2017-- EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
May 22, 2017 General Releases HTML PDF
EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has entered into a $100 million royalty-backed note agreement with HealthCare Royalty Partners (HCR). Under the terms of the transaction, Adamas will receive $35 million at closing and an additional $65 million upon U.S. Fo...
May 11, 2017 General Releases HTML PDF
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. "In the first quarter, we continued preparing for the potential approval and commercialization of ADS-5102, which, if approved, will be the first ...
EMERYVILLE, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Operating Officer, Richard A. King. The compensation committee of the company's board of directors granted Mr. King a stock option to purchase 168,750 shares of the company's common stock, ...
May 5, 2017 General Releases HTML PDF
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2017 financial results on Tuesday, May 9, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financi...
May 2, 2017 General Releases HTML PDF
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Richard A. King as Chief Operating Officer, reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive Officer. Mr. King will be responsible for leading the Company's commercial organization and its establish...
Apr 27, 2017 General Releases HTML PDF
-- Results presented in oral platform and poster sessions at the 69th American Academy of Neurology (AAN) Annual Meeting -- -- Results from the pooled analysis showed approximately twice as many ADS-5102 treated patients as placebo treated patients reported complete resolution of ON time with troublesome dyskinesia and OFF time at 12 weeks -- ...
Apr 24, 2017 General Releases HTML PDF
EMERYVILLE, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding upcoming oral platform and poster presentations highlighting pooled data from the Phase 3 EASE LID and EASE LID 3 clinical trials of ADS-5102 (amantadine) extended-release capsules for the treatment of levodopa-induc...
Apr 18, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3 efficacy study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in patients wi...
Mar 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time. The presentation will be we...
Mar 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted a new employee a stock option to purchase 26,250 shares of the company's common stock, at a per share exercise price of $16.97, the closing trading price on M...
Mar 10, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Cowen and Company Health Care Conference in Boston on Monday, March 6, 2017 at 2:00 p.m. Eastern Time. The presentation w...
Mar 1, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2016.  "We expect 2017 to be a pivotal year as we transform from an R&D-focused company to a commercial organization as we anticipate...
Feb 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of additional data from EASE LID 2, its Phase 3 open-label, long-term safety and efficacy study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in...
Feb 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) will present results from its Phase 2 proof-of-concept study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of walking impairment in patients with multiple sclerosis (MS) at the Americas Committee for Treatment and ...
Feb 17, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016 achievements. "We expect 2017 to be a landmark year for Adamas," said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceutical...
Jan 8, 2017 General Releases HTML PDF
-- PDUFA Action Date Set for August 24, 2017 --  -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson's Disease -- EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accept...
Jan 6, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in development for the treatment of partial onset seizures in patients with epilepsy. Derived from the Company's development platform, ADS-4101 is chrono-s...
Jan 3, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Piper Jaffray Healthcare Conference in New York on Tuesday, November 29, 2016 at 9:30 a.m. Eastern Time. The presentation will be web...
Nov 15, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the quarter ended September 30, 2016.  "This was a milestone quarter for the company as we prepared for and submitted our New Drug Application (NDA) for ADS-5102 (amantadine hydrochloride) extended-release ca...
EMERYVILLE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Stifel 2016 Healthcare Conference in New York on Tuesday, November 15th 2016 at 9:30 a.m. Eastern Time. The presentation will be webc...
Nov 1, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, the company's proprietary lead product candidate, for the potential t...
Oct 27, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Monday, November 7, 2016 at 8:00 a.m. Mountain Time. The presentation w...
Oct 24, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Michael F. Bigham, Chairman and Chief Executive Officer of Paratek Pharmaceuticals, Inc., to its Board of Directors.  Mr. Bigham has broad management experience with over 25 years of senior leadership in the biotech...
Sep 22, 2016 General Releases HTML PDF
DUBLIN and EMERYVILLE, Calif., Sept. 22, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that all four dosage strengths of NAMZARIC® (memantine and donepezil hydrochlorides) extended-release capsules that allow patients on donepezil 10 mg to...
Sep 22, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the results of the EASE LID 3 study, the second Phase 3 trial of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).  The tria...
Sep 20, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding two poster presentations highlighting data from EASE LID and EASE LID 3, two completed trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated ...
Sep 12, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that its new Vice President of Corporate Communications and Investor Relations, Martin Forrest, received a grant of an option to purchase 31,875 shares of the company's common stock, at a per share exercise price of $16.13, the closin...
Sep 9, 2016 General Releases HTML PDF
DUBLIN and EMERYVILLE, Calif., Aug. 31, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amne...
Aug 31, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the second quarter of 2016.  "We are pleased with the progress made during the quarter, especially in our ADS-5102 program.  We announced compelling clinical data in both the Phase 3 program in levodopa-induc...
DUBLIN, July 19, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), today announced that the U.S. Food and Drug Administration (FDA) has approved a new, expanded label for NAMZARIC® (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochlor...
Jul 19, 2016 General Releases HTML PDF
EMERYVILLE, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York on Tuesday, July 12 at 8:00 a.m. Eastern Time. The presentation will b...
Jun 29, 2016 General Releases HTML PDF
EMERYVILLE, Calif., June 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease (PD) at the 20th Annual International C...
Jun 22, 2016 General Releases HTML PDF
EMERYVILLE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine HCl) extended-release capsules in individuals with multiple sclerosis (MS) who have impaired walking.  Data from the study suggest that...
Jun 13, 2016 General Releases HTML PDF
EMERYVILLE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease, will be highlighted in two poster present...
May 16, 2016 General Releases HTML PDF
EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016.  Adamas ended the quarter with $169.2 million of cash, cash equivalents, and available-for-sale securities compared to $120.0 million at December...
May 10, 2016 Financial Releases HTML PDF
EMERYVILLE, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received a grant of an option to purchase 67,500 shares of the company's common stock, at a per share exercise price of $14.70, the closing tr...
May 6, 2016 General Releases HTML PDF
Third Randomized Clinical Trial Meets Primary and Key Secondary Endpoints Conference Call and Webcast Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) EMERYVILLE, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today ...
Apr 28, 2016 General Releases HTML PDF
EMERYVILLE, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on Thursday, April 28, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a company update. ...
Apr 27, 2016 General Releases HTML PDF
Anti-dyskinetic Effect Consistent Across Primary and Secondary Outcome Measures EMERYVILLE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its lead Phase 3 study (EASE LID) evaluating ADS-5102 (amantadine HCl) extended-release capsul...
Apr 19, 2016 General Releases HTML PDF
EMERYVILLE, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology, Director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center, will present emerging science abstra...
Apr 14, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the fourth quarter and full year ended December 31, 2015.  Adamas reported a net loss attributable to common stockholders of $51.8 million, or $2.86 per share, for the year ended December 31...
Feb 23, 2016 Financial Releases HTML PDF
EMERYVILLE, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at two upcoming healthcare conferences--The 36th Annual Cowen and Company Healthcare Con...
Feb 22, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today is providing a summary of 2015 corporate highlights and planned future milestones.  Adamas, which is developing new medicines for chronic neurological disorders, utilizes its technology platform to improve the pharmacokine...
Jan 12, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $23.00 per share. Adamas also granted the underwriters a 30-day option to acquire an additional 375,000 shares fro...
Jan 6, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer 2,500,000 shares of its common stock in an underwritten public offering. Adamas expects to grant the underwriters a 30-day option to acquire an additional 375,000 shares. The offering is subject to market ...
Jan 5, 2016 General Releases HTML PDF
EMERYVILLE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that its Phase 3 EASE LID clinical trial evaluating the company's investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Par...
Dec 23, 2015 General Releases HTML PDF
Call Scheduled for Wednesday, December 23 at 8:00 a.m. Eastern Time EMERYVILLE, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on...
Dec 22, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of enrollment in its Phase 3 EASE LID 3 study.  EASE LID 3 is a clinical trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a mot...
Dec 14, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 2, 2015 at 8:30 a.m. Eastern Time. The presentation will be we...
Nov 17, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the third quarter of 2015.  The company reported a net loss attributable to common stockholders of $14.9 million, or $0.81 per share, for the quarter ended September 30, 2015.  In the sa...
Nov 12, 2015 Financial Releases HTML PDF
EMERYVILLE, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc., will present at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Tuesday, November 10, 2015 at 8:30 a...
Oct 27, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced findings from two nonclinical studies that demonstrate the potential of ADS-5102 for the treatment of multiple sclerosis (MS) symptoms. One study demonstrated improvement in walking in in vivo models of MS. D...
Oct 12, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc., will present at BioCentury's NewsMakers in the Biotech Industry Conference in New York on Thursday, September 10, 2015 at 10:30 a.m. Easte...
Aug 27, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the second quarter of 2015. The company reported a net loss attributable to common stockholders of $14.1 million, or $0.78 per share, for the quarter ended June 30, 2015. In the same period last year, the company rep...
Aug 11, 2015 Financial Releases HTML PDF
EMERYVILLE, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a motor complication associated...
Jul 9, 2015 General Releases HTML PDF
EMERYVILLE, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 9,072,697 entitled "Composition and Method for Treating Neurologic Disease." The claims of this patent are directed towards methods for the once-daily adminis...
Jul 7, 2015 General Releases HTML PDF
EMERYVILLE, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. will present at the Cantor Fitzgerald Inaugural Healthcare Conference in New York on Wednesday, July 8, 2015 at 1:00 PM Eastern Time. ...
Jun 24, 2015 General Releases HTML PDF
EMERYVILLE, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional findings from its Phase 2/3 study (EASED) evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a movement disorder associated with the treatment of Parkinson's disease. Patient diary data were analyzed t...
Jun 15, 2015 General Releases HTML PDF
EMERYVILLE, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today the initiation of a Phase 2 clinical trial with ADS-5102 (amantadine HCl) in individuals with multiple sclerosis (MS) who have walking impairment. "We are pleased to initiate this Phase 2 trial in MS patients with walking impairm...
Jun 11, 2015 General Releases HTML PDF
EMERYVILLE, Calif., June 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. will present at the 2015 JMP Securities Life Science Conference in New York on Tuesday, June 23, 2015 at 2:30 PM Eastern Time. The p...
Jun 9, 2015 General Releases HTML PDF
EMERYVILLE, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the first quarter of 2015. "In 2015, we have made continued progress throughout our business, including receiving orphan drug designation for our lead product candidate, ADS-5102, for the treatment of levodopa...
May 13, 2015 Financial Releases HTML PDF
EMERYVILLE, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease. Adamas currently has multiple Phase 3 studies underway evaluati...
Apr 10, 2015 General Releases HTML PDF
EMERYVILLE, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2015 Needham Healthcare Conference in New York on Tuesday, April 14, 2015 at 10:00 AM Eastern Standard Time. The presentation will be webcast live and available...
Apr 9, 2015 General Releases HTML PDF
EMERYVILLE, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that United States Patent and Trademark Office (USPTO) issued US Patent No. 8,987,333 entitled "Composition and Method for Treating Neurological Disease." The claims of this patent are directed towards dosage forms that enable the osmot...
Mar 31, 2015 General Releases HTML PDF
EMERYVILLE, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the year ended December 31, 2014. "We made significant progress in 2014, advancing ADS-5102, our lead wholly-owned product candidate, into pivotal Phase 3 clinical trials for the treatment of levodopa-induced dy...
EMERYVILLE, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results from its Phase 2/3 clinical study of ADS-5102 (EASED) have been published in the online issue of the peer-reviewed journal Movement Disorders. ADS-5102 is initially being developed by Adamas for the treatment of levodopa-indu...
Feb 9, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas, which develops new treatments for neurological disorders, utilizes its technology platform to improve the pharmacokinetic profiles of approved drugs, alon...
Jan 11, 2015 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today that it has received a $30 million milestone payment from Forest Laboratories Holdings Limited, a subsidiary of Actavis plc, based on the recent FDA approval of Namzaric™, formerly known as MDX-8704. Adamas developed a fixed-dose co...
Jan 8, 2015 General Releases HTML PDF
DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combi...
Dec 24, 2014 General Releases HTML PDF
EMERYVILLE, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US 8,895,616; US 8,895,617 and US 8,895,618), bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to n...
Dec 2, 2014 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 3:30 PM Eastern Time. The presentation will be webcast live an...
Nov 18, 2014 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 7:30 AM Mountain Time. The presentation will be webcast live and availab...
Nov 5, 2014 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million...
EMERYVILLE, Calif., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, co...
Oct 28, 2014 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team. Jeffrey (Jeff) Knapp has been named Chief Operating Officer. In this newly created role, Mr. Knapp will continue to lead the build out of the sales and marketing organization, and will also oversee com...
Aug 13, 2014 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockho...
EMERYVILLE, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human s...
Aug 5, 2014 General Releases HTML PDF
EMERYVILLE, Calif., June 16, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time. The presentation will be webcast live and avai...
Jun 16, 2014 General Releases HTML PDF
EMERYVILLE, Calif., June 10, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a condition characterized by involuntary movements without purpose ...
Jun 10, 2014 General Releases HTML PDF
EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 8,741,343 entitled "Method Of Administering Amantadine Prior To A Sleep Period." The claims of this patent are directed towards administration, prior to bedtime...
Jun 9, 2014 General Releases HTML PDF
EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has initiated a pivotal Phase 3 clinical study of ADS-5102 (amantadine HCl), a high-dose, controlled-release version of amantadine for the treatment of patients with Parkinson's disease who have developed levodopa-induced dyskinesia ...
Jun 9, 2014 General Releases HTML PDF
EMERYVILLE, Calif., May 29, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced a poster presentation at the 18th International Congress of Parkinson's Disease and Movement Disorders from June 8 to 12, 2014, in Stockholm, Sweden. The poster (abstract #722) is titled "Rater training and data completeness in the study of ...
May 29, 2014 General Releases HTML PDF
EMERYVILLE, Calif., May 20, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings Limited related to the development of MDX-8704. MDX-8704, a fixed-dosed combination (FDC) of memantine HCl extended release capsules and donepezil HCl, is...
May 20, 2014 General Releases HTML PDF
EMERYVILLE, Calif., May 13, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the quarter ended March 31, 2014. "During the first quarter we continued to develop our lead wholly-owned product candidate, ADS-5102, for the treatment of levodopa-induced dyskinesia in patients with Parkinson's ...
May 13, 2014 Financial Releases HTML PDF
EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phas...
Apr 30, 2014 General Releases HTML PDF
EMERYVILLE, Calif., April 23, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA. The poster (4009), is titled, "Safety and Efficacy Study of...
Apr 23, 2014 General Releases HTML PDF
EMERYVILLE, Calif., April 15, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ...
Apr 15, 2014 General Releases HTML PDF
Emeryville, Calif., April 9, 2014 – Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin tradin...
New York, NY and Emeryville, CA - March 04, 2014 - Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced Forest's submission of a New Drug Application (NDA) to th...
Mar 4, 2014 General Releases HTML PDF
EMERYVILLE, CA, January 9, 2014 - Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (NYSE: FRX) for MDX-8704. MDX-8704 is a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release capsules) and donepezil HCl being developed as a ...
Jan 9, 2014 General Releases HTML PDF
Montreal, Canada and Emeryville, CA, October 02, 2013 - Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED™ clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced ...
Oct 2, 2013 General Releases HTML PDF
Emeryville, Calif., June 18, 2013 - Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl ER) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia R...
Jun 18, 2013 General Releases HTML PDF
Emeryville, Calif., June 10, 2013 - Adamas Pharmaceuticals, Inc. announced today that the Company’s Phase 2/3 EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin™; amantadine HCl extended release) met the study's primary endpoint. ADS-5102 is an inves...
Jun 10, 2013 General Releases HTML PDF
Emeryville, Calif., April 22, 2013 - Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,389,578 entitled "Composition and method for treatment of neurological disease." The claims of this invention are directed towards improved methods for treating Parkinson's disease ...
Apr 22, 2013 General Releases HTML PDF
Emeryville, Calif., March 20, 2013 - Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin™ (amantadine HCl extended release capsules) program demonstrating the benefit of amantadine in traumatic brain injury (TBI) at the 65th American Academy of Neurology (AAN) Annual Meeting being held in San Diego, CA. Nureli...
Mar 20, 2013 General Releases HTML PDF
NEW YORK & EMERYVILLE, CA, November 13, 2012 - Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended relea...
Nov 13, 2012 General Releases HTML PDF
EMERYVILLE, CALIF., June 4, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its NurelinTM (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute’s (CHI) Targeting Parkinson’s Disease Symposium being held today in Philadelphia. Nurelin, ...
Jun 4, 2012 General Releases HTML PDF
EMERYVILLE, CALIF., May 15, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy studies to be conducted for the registration of Arimenda (memantine HCl extended release and donepezil HCl) capsules. Arimenda, a once-daily...
May 15, 2012 General Releases HTML PDF
EMERYVILLE, CALIF., September 28, 2011 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease. Called E...
Sep 28, 2011 General Releases HTML PDF
EMERYVILLE, CALIF., - April 28, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator...
Apr 28, 2010 General Releases HTML PDF
EMERYVILLE, CALIF., - March 15, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic a...
Mar 15, 2010 General Releases HTML PDF
Emeryville, Calif. - February 22, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and ...
Feb 22, 2010 General Releases HTML PDF
Emeryville, Calif., - August 18, 2009 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influ...
Aug 18, 2009 General Releases HTML PDF
EMERYVILLE, CALIF., August 18, 2009 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, t...
Aug 18, 2009 Financial Releases HTML PDF
Page:
...
Next Last